Population modelling to describe pharmacokinetics of amiodarone in rats: relevance of plasma protein and tissue depot binding.
暂无分享,去创建一个
Amparo Nácher | Virginia Merino | Eduardo Campos Moreno | M. Merino Sanjuán | V. Merino | A. Nácher | Rafael V Martín Algarra | V. Casabó | Eduardo Campos Moreno | Matilde Merino Sanjuán | Vicente G Casabó
[1] M. Lalloz,et al. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands , 1984, The Journal of pharmacy and pharmacology.
[2] G. Hollander,et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. , 2004, Chest.
[3] T. Murakami,et al. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. , 2005, Journal of pharmaceutical sciences.
[4] G. Naccarelli,et al. Amiodarone: clinical trials. , 2000, Current opinion in cardiology.
[5] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[6] G. Tognoni,et al. Clinical Pharmacokinetics of Amiodarone , 1984, Clinical pharmacokinetics.
[7] A. Auricchio,et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. , 1999, The American journal of cardiology.
[8] T. Bouillon,et al. Population pharmacokinetics of long‐term oral amiodarone therapy , 2000, Clinical pharmacology and therapeutics.
[9] L. Sheiner,et al. Estimating bioavailability when clearance varies with time , 1994, Clinical pharmacology and therapeutics.
[10] H. Yamazaki,et al. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[11] V. Casabó,et al. Effects of Surfactants on Amiodarone Intestinal Absorption. I. Sodium Laurylsulfate , 1994, Pharmaceutical Research.
[12] G. Naccarelli,et al. Amiodarone: What have we learned from clinical trials? , 2000, Clinical cardiology.
[13] S. Troy,et al. Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two‐Stage Pharmacokinetic Analysis , 1997, Journal of clinical pharmacology.
[14] A. Nácher,et al. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] D. Brocks,et al. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat‐meal rat models , 2005, Biopharmaceutics & drug disposition.
[16] J. Mason. Drug therapy: amiodarone , 1987 .
[17] S. Shafer,et al. Use of Population Modeling to Define Rational Monitoring of Amiodarone Hepatic Effects , 2004, Clinical pharmacology and therapeutics.
[18] M. Kitakaze,et al. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. , 2005, Biological & pharmaceutical bulletin.
[19] R. Lledo-Garcia,et al. Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[20] H. Karnes,et al. Precision, Accuracy, and Data Acceptance Criteria in Biopharmaceutical Analysis , 1993, Pharmaceutical Research.
[21] K. Williams,et al. Therapeutic drug monitoring: antiarrhythmic drugs. , 1998, British journal of clinical pharmacology.